Sandoz Bolsters its European Essential Medicine Manufacturing Capacity
In the wake of the COVID-19 crisis and the subsequent strain placed on medicine supply chains in Europe, Sandoz – the generics arm of global giant Novartis – has moved…
Address: Vorgartenstraße 206b
A-1020 Wien
,Austria
Tel: +43 (0)1 610 30 – 0
The Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases.
Cardiovascular and metabolic disorders
Through our pharmaceutical research and development efforts, we are developing innovative solutions and medications that can help people around the world living with diabetes, obesity, thrombosis and other chronic and potentially life-threatening conditions.
Immunology
Building upon our long-standing commitment to immunology, we continue to deliver new options to combat complex conditions, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease and psoriasis. Our rich heritage of innovation in biological research and medicines has allowed us to expand to oral and inhaled medicines for immunologic and pulmonary diseases.
Infectious diseases and vaccines
With a goal to improve public health by fighting infectious diseases worldwide, we are dedicated to delivering treatments for people living with HIV/AIDS, hepatitis C, tuberculosis, and other infectious diseases. Recently, we entered the field of prevention with the acquisition of Crucell, a company that develops vaccines and antibodies. As a result, we have a number of marketed vaccines and have furthered our pipeline based on Crucell’s unique technologies.
Neuroscience
With a longstanding, continued commitment to neuroscience, our vision is to reduce the burden, disability and devastation caused by serious neuropsychiatric diseases and pain conditions and restore hope for patients. Our areas of focus include: Neurology, which includes Alzheimer’s disease; psychiatry, focused on mood disorders, such as bipolar disease and major depressive disorder, and schizophrenia; and pain, where we have particular interest in chronic pain states and neuropathic pain.
Oncology
Through groundbreaking research and innovative partnerships, we aim to transform cancer into a preventable, chronic or curable disease. Our goal is to deliver diagnostic and therapeutic options that prolong and improve patients’ lives. We are focused on key cancer types, including ovarian cancer, hematologic malignancies, prostate cancer and lung cancers. We are dedicated to helping realize the promise of winning the “war on cancer.”
In the wake of the COVID-19 crisis and the subsequent strain placed on medicine supply chains in Europe, Sandoz – the generics arm of global giant Novartis – has moved…
Albin Egger, country representative of UCB Pharma Austria, discusses the strong performance of the Austrian affiliate within the global group, organizational restructuring, and the receptiveness of Austria to UCB’s innovative…
Joy Ladurner, co-director of the NKSE (National Coordination Center for Rare Diseases) in Austria, discusses the rationale behind Austria’s prioritization of rare diseases and its leading role in the field.…
Alexander Biach, chairman of the Main Association of Austrian Social Security Institutions, discusses handling the responsibility for Austria’s Europe-leading social security coverage, current inefficiencies that need to be ironed out,…
Gerhard Hirczi of the Vienna Business Agency and Peter Halwachs of LISAvienna describe Vienna’s impressive footprint in the life sciences, its positioning as the start-up hub for Central and Eastern…
Peter Wimmer, country manager of Angelini Austria and Germany, discusses the tailored long-term strategy that this exciting Italian pharmaceutical company is implementing to establish a boutique portfolio and the importance…
Christoph Wahl and Gerlad Weirowski of DHL Global Forwarding Austria discuss the significance of the Austrian affiliate being chosen as lead office for CEE and the company’s life sciences and…
Christoph Sauermann, managing director of Mediclass, an innovative healthcare center, discusses how the complexities of the Austrian healthcare system can be solved through primary healthcare centers, such as Mediclass. Furthermore,…
Rudolf Widmann, CEO and founder of AOP Orphan, the first rare disease-specific European company, discusses the overriding goal to ensure rare disease patients are matched with the correct treatments and…
Barbara Rangetiner and Josef Weinberger of the Austrian affiliate of Octapharma, the largest privately owned human protein products manufacturer in the world, discuss the strategic significance of Austria to the…
Dr. Wolfgang Harrer, regional manager of Chiesi Central and Eastern Europe (CEE), discusses the challenges of managing the region’s diverse cultural differences and the importance of CEE within global operations.…
David Kasper, CEO of ARCHIMEDlife, an innovative Austrian company focused on novel laboratory diagnostics, discusses the innovative solution of a dried blood sample in daily routine diagnostics and novel assays…
See our Cookie Privacy Policy Here